KALV KalVista Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KALV

Price (delayed)

$12.15

Market cap

$512.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.13

Enterprise value

$495.79M

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary ...

Highlights
KalVista Pharmaceuticals's debt has decreased by 16% YoY and by 4.4% QoQ
The EPS has grown by 12% YoY but it has contracted by 3% from the previous quarter
KALV's quick ratio has dropped by 73% year-on-year and by 32% since the previous quarter
KALV's equity has dropped by 52% year-on-year and by 23% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kalvista.com
Peers: OMER OMGA

Key stats

What are the main financial stats of KALV
Market
Shares outstanding
42.19M
Market cap
$512.59M
Enterprise value
$495.79M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.74
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$108.3M
EBITDA
-$107.49M
Free cash flow
-$97.15M
Per share
EPS
-$3.13
Free cash flow per share
-$2.8
Book value per share
$2.56
Revenue per share
$0
TBVPS
$3.28
Balance sheet
Total assets
$113.97M
Total liabilities
$25.39M
Debt
$6.26M
Equity
$88.58M
Working capital
$84.98M
Liquidity
Debt to equity
0.07
Current ratio
5.44
Quick ratio
3.95
Net debt/EBITDA
0.16
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-72.7%
Return on equity
-86.1%
Return on invested capital
-116.9%
Return on capital employed
-114.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KALV stock price

How has the KalVista Pharmaceuticals stock price performed over time
Intraday
-0.16%
1 week
12.71%
1 month
7.9%
1 year
32.5%
YTD
-0.82%
QTD
2.45%

Financial performance

How have KalVista Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$123.72M
Net income
-$108.3M
Gross margin
N/A
Net margin
N/A
KalVista Pharmaceuticals's net income has decreased by 19% YoY and by 8% from the previous quarter
KALV's operating income is down by 17% YoY and by 5% QoQ

Growth

What is KalVista Pharmaceuticals's growth rate over time

Valuation

What is KalVista Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.74
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 12% YoY but it has contracted by 3% from the previous quarter
The P/B is 90% higher than the 5-year quarterly average of 2.5 and 48% higher than the last 4 quarters average of 3.2
KALV's equity has dropped by 52% year-on-year and by 23% since the previous quarter

Efficiency

How efficient is KalVista Pharmaceuticals business performance
KalVista Pharmaceuticals's return on invested capital has shrunk by 76% YoY and by 18% QoQ
KalVista Pharmaceuticals's return on equity has shrunk by 61% YoY and by 28% QoQ
The ROA has shrunk by 51% YoY and by 24% QoQ

Dividends

What is KALV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KALV.

Financial health

How did KalVista Pharmaceuticals financials performed over time
KALV's quick ratio has dropped by 73% year-on-year and by 32% since the previous quarter
KalVista Pharmaceuticals's current ratio has shrunk by 67% YoY and by 25% QoQ
KalVista Pharmaceuticals's debt is 93% lower than its equity
The debt to equity has soared by 75% YoY and by 17% from the previous quarter
KALV's equity has dropped by 52% year-on-year and by 23% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.